This application is a resubmission of the application submitted in response to RFA-CA-09-022. We appreciate the comments from the reviewers following that submission. The areas of concern have been reviewed and we have reworked the document to address those areas. The VMCCOP has been in existence since 1983 and is one of 27 CCOP grants continuously funded. Our CCOP is comprised of 6 hospital based practices spanning over Washington and Alaska. The VMCCOP core component is comprised of Virginia Mason Medical Center (VMMC) and 5 additional satellite locations in the greater Seattle area. Our component sites include Fairbanks Cancer Treatment Center (Fairbanks Memorial Hospital), Fairbanks AK;Providence Cancer Center (Providence Alaska Medical Center), Anchorage AK;Evergreen Medical Center, Kirkland WA;Valley Medical Center, Renton WA;and Pacific Medical Center, Seattle WA. It is the intent of the VMCCOP to continue to expand clinical research opportunities for our cancer patients.
Specific aims of the VMCCOP are outlined below: 1. Maintain and continue our growth in enrollment to treatment and cancer control trials. 2. Increase affiliation participation surrounding enrollment and national participation. 3. Continue to improve our quality and data integrity surrounding our clinical trials. 4. Improve upon our research efficiency by creating standards surrounding study start-up, coordinator hand-offs and subject visits.
It is estimated that there will be 1,529,560 new cancer cases diagnosed in the United States in 2010, and 569,490 cancer deaths. In providing access to clinical research trials in the treatment and prevention of cancer to the patient population throughout Washington and Alaska, the VMCCOP hopes to contribute to reductions in cancer incidence and mortality.
|Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7|
|Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42|
|Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7|
|Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8|
|Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9|
|Quinn, David I; Tangen, Catherine M; Hussain, Maha et al. (2013) Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol 14:893-900|
|Stiff, Patrick J; Unger, Joseph M; Cook, James R et al. (2013) Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 369:1681-90|
|Zirpoli, Gary R; Brennan, Patrick M; Hong, Chi-Chen et al. (2013) Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat 137:903-13|
|Hussain, Maha; Tangen, Catherine M; Berry, Donna L et al. (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368:1314-25|
|Press, Oliver W; Unger, Joseph M; Rimsza, Lisa M et al. (2013) Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol 31:314-20|
Showing the most recent 10 out of 114 publications